Follow on Google News News By Tag * Stem * Ihbt * Avgn * Penny Stocks * Hot Stocks * Small-cap * Micro-cap * Best Penny Stocks To Buy * Investor Relations * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News |  Penny Stocks Alert – Hot Stocks Alert for STEM, IHBT, AVGNMobile Press Wire issues Hot Stocks and Penny Stocks alerts for emerging public companies on the move
By: MobilePressWire.com To Receive FREE Stock Alerts specially formatted for you mobile phone before others, please see below or go to http://www.mobilepresswire.com for more details. StemCells NEWS – December 18, 2008 Breaking Hot Stocks Alert: Breaking Hot Stocks Alert: StemCells Obtains FDA Approval to Begin Clinical Trials for Treatment of a Fatal Brain Disorder PALO ALTO, Calif., Dec 18, 2008 (BUSINESS WIRE) -- StemCells, Inc. released breaking news this morning that it has just has received approval from the U.S. Food and Drug Administration (FDA) to start clinical trials of its product for purified human neural stem cells (HuCNS-SC) to treat a fatal brain disorder that mainly affects young children. This Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for the disorder, Pelizaeus-Merzbacher Disease (PMD). Investor's are urged to watch for early movement with this stock as it closed Wednesday December 17, 2008 at $1.32per share. StemCells, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. The company engages in product development programs for two cell types: the human neural stem cell and human liver engrafting cells. In its central nervous system Program, the company is conducting a Phase I clinical trial to evaluate the safety and preliminary efficacy of its HuCNS-SC product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis. The company recently announced it has closed the sale of 13,793,104 units to certain institutional investors at a price of $1.45 per unit, for gross proceeds of $20.0 million. Each unit consists of one share of common stock and one five-year warrant to purchase 0.75 share of common stock at an exercise price of $2.30 per share. To read the entire release regarding the company's news and to sign up to get FREE alerts like this sent to your cellular device before others are able to view it, visit: http://mobilepresswire.com/ Inhibiton Therapeutics NEWS – December 18, 2008 Penny Stocks Alert: Inhibiton Therapeutics Executes Agreement to Acquire Alternative Energy Company Englewood, CO- Inhibiton Therapeutics, Inc. released news this morning that the company has execute a Letter of Intent (LOI) to acquire HPI Partners, LLC and its subsidiary AlumiFuel Power, Inc. HPI Partners, through AlumiFuel, is an alternative energy company that is working to commercialize a process for generating hydrogen gas and steam on-site and on-demand for multiple niche applications. Investor's are urged to watch for early movement with this stock as it closed Wednesday December 17, 2008 at $0.10 per share. Inhibition Therapeutics, Inc., a nominally capitalized development stage company focused on biotechnology research, engages in the research and development of cancer therapeutic agents and cancer fighting drugs called targeted therapies. The targeted therapies identify molecular causes of cancer and inhibit the signals that cancer cells need to multiply. Terms of the Agreement call for the members of HPIP to receive up to $12 million of Inhibiton common stock in exchange for all of the outstanding membership interests in HPIP including ownership of AlumiFuel and its intellectual property and business operations. Completion of this transaction is subject to further due diligence, the negotiation and execution of a definitive acquisition agreement, any necessary board of director, stockholder or member approvals, and other customary closing conditions. To read the entire release regarding the company's recent announcement and to sign up to get FREE alerts like this sent to your cellular device before others are able to view it, visit: http://mobilepresswire.com/ Avigen NEWS - December 18, 2008 Small Cap Alert: Avigen Sells Early Stage Blood Coagulation Compound to Baxter ALAMEDA, Calif -- Avigen, Inc. , released breaking news this morning it has sold the rights to its early stage blood coagulation compound, AV513, to Baxter Healthcare Corporation for $7 million. Baxter, a global leader in hemophilia therapy, acquired all rights to AV513. Avigen has been developing AV513 as an oral therapy to treat patients with bleeding disorders, including hemophilia A. Investor's are urged to watch for early movement with this stock as it closed Wednesday December 17, 2008 at $0.61 per share. Avigen, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of small molecule therapeutics to treat neurological and neuromuscular disorders. The company is developing AV650 under license and supply agreement with SDI Diagnostics International, LTD. for the treatment of spasticity and painful muscle spasms in North America; AV411 for the treatment of neuropathic pain and other neurological disorders; and AV513 for the treatment of bleeding disorders, including hemophilia. To read the entire release regarding the company's recent announcement and to sign up to get FREE alerts like this sent to your cellular device before others are able to view it, visit: http://mobilepresswire.com/ ABOUT MOBIWIRE MobiWire is solely owned and operated by Mobile Press Wire a leading news alert wire service for mobile phones subscribers. Mobile Press Wire offers FREE news alerts for its subscribers of publicly traded companies that wish to instantly announce special news to the investment community. Visit http://www.mobilepresswire.com for more details. GET NEWS NOW, GET NEWS FAST, GET NEWS BEFORE OTHERS... To get FREE Mobile Stock Alerts formatted especially for your cell phone; text the word "STOCKS" in the subject line to 68494. Please note subscribers are never charged any fees from Mobile Press Wire for signing up to receive public company alerts or canceling any of our services. Standard carrier SMS text messaging rates may apply. Please check with your wireless plan for further details. Subscribers are able to fully control the number of alerts they want to receive. Choose to get 1 a week, 2 a week, 5 a week and so on. Subscribers are also able to stop receiving alerts at anytime with no questions asked by texting the word STOP to 68494. Contact email: info@mobilepresswire.com URL: http://www.mobilepresswire.com Company: MobiWire # # # Mobile Media Technology Solutions. Utilizing proprietary SMS Text Message Services, we deliver breaking news alerts for Public Companies and Investor Relations Professionals via specially formatted text messages. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||
